RPEAX
Price
$44.25
Change
-$0.09 (-0.20%)
Updated
Jul 13 closing price
Net Assets
654.39M
VSTSX
Price
$354.42
Change
-$2.83 (-0.79%)
Updated
Jul 13 closing price
Net Assets
2.3T
Interact to see
Advertisement

RPEAX vs VSTSX

RPEAX vs VSTSX Comparison Chart in %
View a ticker or compare two or three
VS
RPEAX vs. VSTSX commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RPEAX is a Buy and VSTSX is a Hold.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
VSTSX has more cash in the bank: 2.3T vs. RPEAX (654M). VSTSX pays higher dividends than RPEAX: VSTSX (1.07) vs RPEAX (0.68). RPEAX was incepted earlier than VSTSX: RPEAX (32 years) vs VSTSX (10 years). RPEAX (0.94) is less costly to investors than VSTSX (0.01). RPEAX is a more actively managed with annual turnover of: 18.00 vs. VSTSX (3.00). RPEAX has a lower initial minimum investment than VSTSX: RPEAX (1000) vs VSTSX (5000000000). VSTSX annual gain was more profitable for investors over the last year : 21.48 vs. RPEAX (10.27). VSTSX return over 5 years is better than : 66.56 vs. RPEAX (1.22).
RPEAXVSTSXRPEAX / VSTSX
Total Expense Ratio0.940.019,400%
Annual Report Gross Expense Ratio0.940.019,400%
Fund Existence32 years10 years-
Gain YTD12.14011.205108%
Front Load5%N/A-
Min. Initial Investment100050000000000%
Min. Initial Investment IRAN/AN/A-
Net Assets654M2.3T0%
Annual Yield % from dividends0.681.0764%
Returns for 1 year10.2721.4848%
Returns for 3 years21.5867.0632%
Returns for 5 years1.2266.562%
Returns for 10 years57.85239.5324%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PWCIX95.22N/A
N/A
Principal Capital Appreciation Inst
PRLAX24.44N/A
N/A
T. Rowe Price Latin America
PACLX37.66N/A
N/A
T. Rowe Price Capital Appreciation Adv
RLIEX20.52N/A
N/A
Lazard International Equity R6
MCYIX16.37-0.51
-3.02%
NYLI Candriam Emerging Markets Eq Cl I